AZD4573
Phase 1CompletedDevelopment Stage
Relapsed or Refractory Haematological Malignancies Including
Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, High Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Richter's Syndrome, B-cell Non-Hodgkin Lymphoma, T-cell Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Multiple Myeloma
Oct 24, 2017 โ Sep 30, 2021
About AZD4573
AZD4573 is a phase 1 stage product being developed by AstraZeneca for Relapsed or Refractory Haematological Malignancies Including. The current trial status is completed. This product is registered under clinical trial identifier NCT03263637. Target conditions include Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia.
Hype Score Breakdown
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05140382 | Phase 2 | Completed |
| NCT03263637 | Phase 1 | Completed |
Competing Products
20 competing products in Relapsed or Refractory Haematological Malignancies Including